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Bisphosphonates are analogues of pyrophosphate and, like
pyrophosphate, are strongly bound to hydroxyapatite on the
surface of bone. In contrast to pyrophosphate, which is rapidly
hydrolysed by phosphatases, bisphosphonates are stable and
reduce the number and activity of osteoclasts by various means.
This inhibition of bone resorption forms the pharmacological basis
for the treatment of tumour-induced osteolysis (Rodan and
Fleisch, 1996; Fleisch, 1997). Bisphosphonates provide an osteo-
protective effect for the remaining healthy skeleton and can
support the remineralization of those bone sections with existing
metastatic involvement (Averbuch, 1993; Kanis, 1995).
The ability of bisphosphonates to reduce skeletal morbidity has
been shown in numerous clinical trials, particularly in patients
with metastatic breast cancer and multiple myeloma. Irrespective
of the specific agent or of the route of administration (oral or intra-
venous), skeletal complications were reduced by some 25–50%
(Paterson et al, 1993; Van Holten-Verzantvoort et al, 1993;
Berenson et al, 1996, 1998; Hortobagyi et al, 1996, 1998;
Bloomfield, 1998; McCloskey et al, 1998). None of the studies,
however, was sufficiently powered to demonstrate statistically a
benefit in terms of survival of breast cancer patients treated with
bisphosphonates except in subgroups.
PATHOPHYSIOLOGY OF METASTATIC BONE
DISEASE
All malignant tumours are potentially capable of metastatic spread
to bone, but some have a special predilection to target the skeleton
specifically. Breast, prostate, lung, thyroid and renal cell cancers
and multiple myeloma all belong to this group, and are jointly
responsible for 80–90% of all bone metastases (Weiss and Gilbert,
1981; Galasko, 1986). Apart from the fact that, in the vast majority
of cases, metastasis is an indication for incurability, the complica-
tions of bone metastases severely affect the quality of life of
patients. In breast cancer for example, the commonest complica-
tion is bone pain, which affects almost 90% of the patients; some
25% suffer from a pathological fracture or spinal compression
syndromes, whereas bone marrow infiltration with suppression
of haematopoiesis is observed in 10% of patients. Furthermore,
10–20% of affected women suffer from hypercalcaemic episodes.
Tumour osteolysis represents the morphological consequence of
these complications (Coleman and Rubens, 1985, 1987; Theriault
and Hortobagyi, 1992).
Bone metastases develop according to the same criteria applic-
able to other metastases, i.e. the tumour releases cells which
migrate through the extracellular matrix and penetrate the base-
ment membrane. They are then transported to distant organs via
the circulation. In the target organ the process operates in reverse:
the metastatic cells enter the perivascular space and are deposited
there. This process is mediated partly by adhesion molecules and
partly by chemotaxis (Rubens, 1992). Although most of the
disseminated cells perish, a few cells are capable of producing
micrometastatic proliferation, or remain dormant, only to grow at
a later stage. In 30–45% of patients with breast cancer such cells
are found in the bone marrow, although it has not yet proved
possible to differentiate between those cells that perish and the
remainder that remain capable of proliferation (Diel et al, 1994).
Although our understanding of the processes of tumour cell
dissemination, cell dormancy and the early division phase is
limited, we have nevertheless learned a great deal about the inter-
action between micrometastases in the bone marrow and the bone
and its cell populations. During the early phase of bone metastasis
the bone is destroyed not by the tumour itself but rather by the
osteoclasts that have been activated by substances secreted in a
paracrine and/or autocrine fashion. Of particular importance is
parathyroid hormone-related peptide (PTHrP). This peptide is
produced by breast cancer cells in the bone metastatic site, and is
responsible for osteolysis (Guise et al, 1996). By acting on
immune cells or osteoblasts, paracrine osteoclast activation
directly or indirectly leads to degradation of the mineralized bone
matrix, thereby enabling growth factors and cytokines that were
Review
Bisphosphonates in the adjuvant treatment of cancer:
experimental evidence and first clinical results
IJ Diel1 and GR Mundy2 for the International Bone and Cancer Study Group (IBCG)*
1Department of Ob/Gyn, University of Heidelberg, Voss-str 9, 69115 Heidelberg, Germany; 2University of Texas, Health Science Center, San Antonio, TX, USA
Summary Several animal models, as well as a number of cell culture experiments, indicate a prophylactic effect of bisphosphonates in
respect of subsequent bone metastasis. Moreover, in preliminary clinical trials involving patients with advanced breast cancer and local or
remote metastases, biophosphonates produced a reduction in new skeletal metastases. This overview summarizes and discusses the results
of the latest investigations. It opens with a section on the pathophysiology of bone metastasis, which is followed by a report on animal models
and first studies of bisphosphonate treatment as a new approach in systemic adjuvant therapy. © 2000 Cancer Research Campaign
Keywords: bone metastases; bisphosphonates; prevention; prophylaxis
1381
Received 24 May 1999
Revised 11 October 1999
Accepted 4 November 1999
Correspondence to: IJ Diel *See Appendix.
British Journal of Cancer (2000) 82(8), 1381–1386
© 2000 Cancer Research Campaign
DOI: 10.1054/ bjoc.1999.1077, available online at http://www.idealibrary.com on previously deposited in the bone to accelerate the rate of
proliferation of micrometases. The vicious cycle of dialogue
between tumour cells and bone cells can be interrupted by the
therapeutic use of bisphosphonates, which inhibit osteoclastic
bone resorption and thereby decrease production of active
growth factors in the bone microenvironment (Mundy, 1991,
1995).
IN VITRO STUDIES ON THE CYTOTOXICITY OF
BISPHOSPHONATES
In the first years of bisphosphonate research only few investiga-
tions with cancer cell lines have been able to confirm or refute a
direct cytotoxic effect. As early as 1982, however, Reitsma et al
were able to demonstrate a cytotoxic effect in macrophages. This
effect was achieved with clodronate at therapeutic dosages, and
with pamidronate at much higher dosages. Mönkkönen’s study
group in Finland confirmed this effect of clodronate in numerous
investigations, and also discovered that liposome-encapsulated
clodronate is many times more potent than the free substance. The
same study group also confirmed a cytotoxic effect for etidronate
and pamidronate in the liposome-encapsulated form (Mönkkönen
et al, 1994). Several studies in recent years have confirmed that the
cytotoxic effect in both macrophage-like cells and osteoclasts is
achieved by the induction of apoptotic processes (Coxon et al,
1995; Hughes et al, 1995; Rogers et al, 1996). Interestingly, there
appear to be differences between the various bisphosphonates.
Clodronate induces both necrotic and apoptotic cell death
following metabolism to the non-hydrolysable ATP analogue
adenosine 5¢-(beta, gamma-dichloromethylene)-triphosphate
(Selander et al, 1996; Frith et al, 1997). In the case of aminobis-
phosphonates, apoptosis seems to be caused by inhibition of the
mevalonate pathway with subsequent prevention of prenylation
(Luckman et al, 1998; Benford et al, 1999; Rogers et al, 1999).
There are now several studies in myeloma and breast cancer cell
lines that underline this effect for both clodronate and the amino-
bisphosphonates (Shipman et al, 1997, 1998; Aparico et al, 1998;
Busch et al, 1998; Fromigue et al, 1999). It is not yet clear whether
this effect merely represents an additional explanation for the
mode of action of bisphosphonates or whether the apoptosis of
macrophage-like cells and osteoclasts can produce a change in the
microenvironment of tumour cells.
Furthermore, two recently published investigations have shown
that bisphosphonates change the adhesion properties of tumour
cells and the bone surface. Van der Pluijm et al (1996) incubated
bone disks with various bisphosphonates and subsequently
observed that the disks were resistant to the adhesion properties of
tumour cells. The strongest effect was produced by ibandronate
and the weakest effect by clodronate. Boissier et al (1997) investi-
gated the adhesion properties of breast and prostate cancer cell
lines. After pretreatment with clodronate the adhesiveness of the
cells was drastically reduced. There have been no reports to
confirm whether this effect of bisphosphonates on adhesion
molecules also affects tumour cells that have already dissemi-
nated. This question requires investigation in animal models.
ANIMAL STUDIES
The first evidence confirming a reduction in osteolytic lesions as a
result of early bisphosphonate therapy was observed with
etidronate (Guaitani et al, 1984; Jung et al, 1984). Using a mouse
tumour model and bladder tumour cells, Nemoto et al (1987)
showed a reduction in the extent of tumour osteolysis and a
prolongation of survival time in treated animals. But the relatively
weak effect of etidronate and the impairment of mineralization
resulting from its use became apparent at a very early stage in the
experiments.
Comprehensive studies on the osteoprotective action of
clodronate were conducted by Krempien’s study group (Krempien
and Manegold, 1993; Krempien, 1994, 1996). In numerous
experiments with the PTHrP-producing Walker carcinosarcoma
256, bone was inoculated with tumour cells and the effects
subjected to histological investigation. The extent of bone
destruction was markedly reduced by pretreatment with bisphos-
phonates. The degree of destruction correlated with the duration
and intensity of the clodronate treatment. The longer the
treatment-free interval, the weaker the protective effect on bone.
The study group viewed this finding as evidence that a continuous
supply of bisphosphonates was more beneficial than interval
therapy in terms of prophylaxis.
Krempien and Wingen were also able to show the same osteo-
protective effect with pamidronate in the hypercalcaemic Walker
tumour. No difference was detected between pamidronate and
other bisphosphonates (Wingen et al, 1986; Krempien et al, 1988).
Kostenuik et al (1993) investigated the efficacy of pamidronate
in rat bone after the injection of Walker cells. Fisher rats were
pretreated for 7 days with pamidronate (0.5 mg kg–1) and then
given an intramuscular injection of tumour cells. Two weeks later
the animals were sacrificed and the bones subjected to histological
analysis. Compared to the controls, the cancerous bone volume
was three times higher in the animals pretreated with pamidronate.
Contrary to expectation, the tumour mass was increased in the
pretreated animals without any demonstrable effects on
extraosseous metastases.
Contrasting results were reported by Sasaki et al (1995) who
observed a reduced tumour burden in bone in nude mice pretreated
with the bisphosphonate risedronate and subsequently given an
intracardiac injection of cells from a human breast cancer cell line
(MDA-MB-231). In a second experiment, risedronate was only
administered after the appearance of the first bone metastasis. In
both trials, the administration of the bisphosphonate delayed or
reduced the occurrence of further skeletal metastases. The
pretreated animals also survived for a significantly longer period.
Similar findings were observed with the bisphosphonate iban-
dronate (Yoneda et al, 1997).
In another animal model, Müller et al (1996) inhibited the
intraperitoneal growth of myeloma cells by continuous
pamidronate injections. In some cases the tumour weight in the
test group was reduced by over 50% compared to the controls.
Moreover, Hall and Stoica (1994) showed bisphosphonates to be
capable of reducing the number, extent and size of bone
metastases. In their experiments rats also received an intracardiac
injection of a breast cancer cell line (ENU 1564). Thereafter, the
animals received the bisphosphonate risedronate, whereas the
control animals received physiological saline solution. After 4
weeks the rats were sacrificed and the pattern of metastasis
evaluated. Although visceral dissemination was identical in both
groups, the animals receiving the adjuvant treatment showed
considerably fewer bone metastases (n = 33) than the control
group (n = 151). In addition, 30% of the biphosphonate-treated
rats were completely free of skeletal metastases, compared to just
16% of the control rats.
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can prevent the development of bone metastases in various animal
models. These studies justify clinical studies of bisphosphonates
as prophylactic agents.
FIRST CLINICAL TRIALS
At present, the therapy of tumour osteolysis and associated
complications is still highly unsatisfactory and is of a purely
palliative nature. In this respect it could therefore be very worth-
while to carry out early osteoprotection, at least in patients at a
high risk of subsequent skeletal metastasis. Older clinical trials
provided initial evidence that patients who were treated with
bisphosphonates developed fewer new metastases. In particular,
Elomaa et al (1983, 1987) observed this effect after administration
of clodronate in a controlled non-randomized study in patients
with breast cancer and osseous metastases, although it should be
pointed out that the number of patients in each group was small.
Following discontinuation of the bisphosphonate, the number of
new metastases in the two groups became similar.
SECONDARY PREVENTION OF METASTASES
The osteoprotective effect of clodronate was first investigated in a
double-blind, randomized, placebo-controlled study by Kanis et al
(1996). The trial was carried out in patients with advanced breast
cancer and local or distant metastases who did not have bone
metastases. Sixty-six women received 1600 mg clodronate orally
per day for 3 years, whereas 67 women received a placebo for the
same period. At the end of treatment it was found that there were
fewer new bone metastases in the clodronate group than in the
control group (15 vs 19) and that the overall number of metastases
was also lower (32 vs 63; P > 0.005). As expected, the number of
skeletal complications was also lower in the clodronate group.
A non-placebo-controlled, randomized study in patients with
breast cancer and already evident bone metastases was published
by Conte et al (1996). In this study, 152 patients received
chemotherapy and 145 patients received chemotherapy supple-
mented by infusions of 45 mg pamidronate every 3 weeks. The
therapy was continued at least until there was renewed skeletal
progression. Although the dosage of pamidronate was low, evalua-
tion of the study revealed prolongation of the skeletal recurrence-
free interval (249 vs 168 days; P = 0.02) and the complication-free
interval (533 vs 490 days); but not a reduction in the number
of new metastases. A study published in 1996 by Van Holten-
Verzantvoort et al (1996) also failed to show a reduction in the
number of metastases. In this study, 142 patients with breast
cancer with advanced local or distant disease but without bone
metastases were enrolled and were given either continual treat-
ment with 300 mg pamidronate orally or were simply followed up.
At the end of the study there were no signs of a reduction in the
frequency of metastases. Similar (negative) results were also seen
in two trials in 304 myeloma patients and in 610 women with
advanced breast cancer but without skeletal metastasis (Ford et al,
1998). Following randomization, the myeloma patients received
either 300 mg pamidronate or placebo, whereas the breast cancer
patients received either 150 mg pamidronate or placebo (for an
unlimited period). Both studies failed to show a reduction in the
prevalence of bone metastases. It would, however, be wrong to
conclude on this basis that pamidronate is ineffective in the
prophylactic setting. Pamidronate is extremely poorly absorbed
(< 1%) when given by the oral route. At doses of 600 mg, oral
pamidronate is effective in the treatment of tumour osteolysis, but
the adverse drug reactions (oesophagitis and gastritis with ulcera-
tion) are unacceptable. It is likely that prophylactic studies with
intravenous pamidronate might produce better results.
PRIMARY PROPHYLAXIS OF METASTASES
The first study of the adjuvant use of bisphosphonates in breast
cancer was presented in 1997 and has been published since then
(Diel et al, 1998). In this trial, which was randomized but not
placebo-controlled, 157 patients were treated with 1600 mg
clodronate orally per day for 2 years and a further 145 patients
served as controls. At the time of primary surgery all patients had
immunocytologically detectable tumour cells in bone marrow
(minimal residual disease) and were therefore at a high risk of
subsequent metastasis (Diel et al, 1996). The study was evaluated
after a median follow-up period of 36 months. In the bisphospho-
nate group there was a significant reduction in both the number of
bone metastases (P = 0.003), and in the number of non-osseous
metastases (P = 0.003; overall survival P < 0.001). Furthermore,
the number of bone metastases per patient was only half as high in
the bisphosphonate group as in the control group (3.1 vs 6.3). The
authors were surprised by the significant reduction in visceral
metastases and suggested that this effect might be due to a cyto-
toxic effect of chemotherapy and hormone therapy. There is
evidence from animal experiments to support this hypothesis
(Wingen et al, 1988; Stearns and Wang, 1996).
Some of the results of the Heidelberg study have been
confirmed in a report presented at the 1998 ASCO Meeting. In a
controlled double-blind study, 1079 women with primary breast
cancer received either 1600 mg clodronate or a placebo in addition
to standard systemic therapies. In an initial analysis of this
Canadian–British–Scandinavian study, there was also a significant
reduction in the incidence of bone metastases (Powles et al, 1998).
The effect was slightly better in post-menopausal women. With
regard to the reduction in visceral metastases, the authors found a
trend, but no significant differences. The overall survival time was
the same in both groups. At the 1999 ASCO Meeting a third study
from Finland was presented that generated completely different
results (Saarto et al, 1999). In this trial with 299 patients with
node-positive primary breast cancer were also treated with
1600 mg clodronate orally (but for 3 years). The results showed no
significant differences with regard to the incidence of bone metas-
tases but indicated a significant increase in visceral metastasis and
a deterioration in overall survival.
To this time, no such harmful effects of clodronate have been
reported, either in preclinical or clinical trials. Saarto’s prevention
study is the first of its kind. Should a deleterious effect actually
exist, it would have an immense impact, since it might affect other
bisphosphonates as well as clodronate. Furthermore, such an effect
could not be ignored if the substances are used over a period of
years in osteoporosis.
Even so, and neither can this go unmentioned in the analysis of
the study Saarto/Elomaa, the best effect was still seen with regard
to bone metastases (i.e. not a significant deterioration). Following
careful consideration, only methodological differences can explain
why the three prophylaxis studies arrived at different results. Only
a relatively small number of patients were enrolled (about 300 in
each case) in both the Heidelberg and the Finnish studies, neither
of which was double-blind. Such small numbers can produce
random results. From a methodological point of view the Powles
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its results lie between those from Heidelberg and those from the
Finnish group. The inclusion criteria were different in all three
studies. In the largest study, all patients with primary breast cancer
were enrolled, compared with node-positive patients in the Finnish
study and patients with tumor cells in the bone marrow at the time
of surgery in the Heidelberg study. Speculating about micrometas-
tasis as a therapeutic target, this last group of patients could have
the best preconditions for prophylaxis, since an apoptotic effect of
bisphosphonates accumulated on the bone surface could have an
influence on the individual tumour cells.
Because of their contradictory results, the three adjuvant studies
indicate the urgent need for new randomized, placebo-controlled
studies to confirm or refute the preliminary findings.
ARGUMENTS FOR THE ADJUVANT USE OF
BISPHOSPHONATES
The efficacy and tolerability of most drugs that are presently used
in adjuvant systemic therapy of primary malignancies were previ-
ously tested in patients in a palliative setting. This is also likely to
be the case with the bisphosphonates. There are now numerous
studies that demonstrate the effectiveness of the individual bis-
phosphonates in preventing skeletal complications. The reduction
in symptoms by about 25–50% testifies to the efficacy of the
bisphosphonates. In comparison to cytotoxic agents, the number
and incidence of complications and side-effects are extremely low
with bisphosphonates, with levels similar to those reported for
tamoxifen. To date, no study has shown any signs of the long-term
toxicity on bone that was initially feared with this group of agents.
In addition, bisphosphonates are also used for non-oncological
indications (e.g. Paget’s disease, osteoporosis).
The occurrence of cancer treatment-induced hypogonadism
(chemotherapy, endocrine therapy) is an extremely important
factor for affected patients, but currently receives too little atten-
tion. This may later cause osteoporosis with all the associated
complications. Long-term osteoprotection, which can be provided
by bisphosphonates, is likely to be helpful in such patients (Saarto
et al, 1997).
Animal experiments and initial clinical experience indicate that
it is worthwhile to pursue further the question of adjuvant therapy
with bisphosphonates. It is not clear whether the major action of
the drugs is via a direct cytotoxic effect or via inhibition of growth
of micrometastatic cells by changing the microenvironment.
However, all investigations to date suggest that it is important to
treat the metastatic target organs as well as the primary tumour.
The skeleton, with its clear interaction between bone cells and
metastatic tumour cells, offers an excellent model for this
approach.
It is important to confirm the first but encouraging results of
adjuvant bisphosphonate therapies. Candidates for such studies are
patients with tumours that metastasize to bone, in particular breast,
lung and prostate cancer, and patients with multiple myeloma. In
order to obtain beneficial results it would be best to start by
recruiting patients at a high risk of metastasis, i.e. oestrogen
receptor-positive breast cancer patients with regional lymph node
involvement, local progression or presence of tumour cells in bone
marrow.
Another method would be to enroll patients with elevated levels
of specific prognostic markers for bone metastases. Several
studies have shown that these might be patients with primary
tumours that produce immunoreactive PTHrP. Patients with
PTHrP-positive breast cancers develop bone metastases signifi-
cantly more frequently than patients with PTHrP-negative tumours
(Bundred et al, 1992). Recently it has been suggested that PTHrP
positivity may provide a survival advantage (Henderson et al,
1999). A further promising prognostic factor could be the detec-
tion of bone sialoprotein (BSP) in the serum of patients with
primary breast cancer. In a first study, it has been reported that
patients who subsequently developed skeletal metastases had
increased serum BSP (Diel et al, 1998). However, because cross-
laps (collagen degradation fragments in serum) were elevated in
some patients, it is not completely clear whether some of the
serum BSP detected is derived from the bone metabolism rather
than from the primary tumour (Diel et al, 1999). This could mean
that BSP is also an early marker for an onsetting bone metastasis.
Possibly, BSP is both a prognostic factor and an early marker, and
thus identifies a risk group that would profit from preventive
bisphosphonate therapy.
At present it is unclear whether this type of adjuvant therapy
with bisphosphonates should be given continually by the oral
route, or whether an intravenous interval therapy could produce
the same results. It is also uncertain whether the doses used in a
palliative setting are optimal or whether lower doses might also
suffice. The optimum period of adjuvant treatment is also subject
to debate. What is clear, however, is that confirmation of the initial
clinical results will open a new chapter in the treatment of malig-
nant tumours.
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